Research Article | Open Access
Mostafa Z. Badr, Alexander Shnyra, Mikhail Zoubine, Maxim Norkin, Betty Herndon, Tim Quinn, Roberto N. Miranda, Michael L. Cunningham, Agostino Molteni, "Phthalate-Induced Liver Protection against Deleterious Effects of the Th1 Response: A Potentially Serious Health Hazard", PPAR Research, vol. 2007, Article ID 049671, 6 pages, 2007. https://doi.org/10.1155/2007/49671
Phthalate-Induced Liver Protection against Deleterious Effects of the Th1 Response: A Potentially Serious Health Hazard
Infection with Mycobacterium tuberculosis (TB) induces pulmonary immunopathology mediated by classical Th1 type of acquired immunity with hepatic involvement in up to 80% of disseminated cases. Since PPAR agonists cause immune responses characterized by a decrease in the secretion of Th1 cytokines, we investigated the impact of activating these receptors on hepatic pathology associated with a well-characterized model of Th1-type pulmonary response. Male Fischer 344 rats were either maintained on a drug-free diet (groups I and II), or a diet containing diethylhexylphthalate (DEHP), a compound transformed in vivo to metabolites known to activate PPARs, for 21 days (groups III and IV). Subsequently, animals were primed with Mycobacterium bovis purified protein derivative (PPD) in a Complete Freund's Adjuvant. Fifteen days later, animals in groups II and IV were challenged with Sepharose 4B beads covalently coupled with PPD, while animals in groups I and III received blank Sepharose beads. Animals with Th1 response (group II) showed a marked structural disruption in the hepatic lobule. Remarkably, these alterations were conspicuously absent in animals which received DEHP (group IV), despite noticeable accumulation of T cells in the periportal triads. Immunostaining and confocal microscopy revealed hepatic accumulation of IFN Th1 and IL- Th2 cells in animals from groups II and IV, respectively. Our data suggest a PPAR-mediated suppression of the development of a Th1 immune response in the liver, resulting in hepatoprotective effect. However, potentially negative consequences of PPAR activation, such as decreased ability of the immune system to fight infection and interference with the efficacy of vaccines designed to evoke Th1 immune responses, remain to be investigated.
- C. Levine, “Primary macronodular hepatic tuberculosis: US and CT appearances,” Gastrointestinal Radiology, vol. 15, no. 1, pp. 307–309, 1990.
- B. Qiu, K. A. Frait, F. Reich, E. Komuniecki, and S. W. Chensue, “Chemokine expression dynamics in mycobacterial (type-1) and schistosomal (type-2) antigen-elicited pulmonary granuloma formation,” American Journal of Pathology, vol. 158, no. 4, pp. 1503–1515, 2001.
- S.-L. Tsai, Y.-F. Liaw, M.-H. Chen, C.-Y. Huang, and G. C. Kuo, “Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity,” Hepatology, vol. 25, no. 2, pp. 449–458, 1997.
- H. Tsutsui, K. Adachi, E. Seki, and K. Nakanishi, “Cytokine-induced inflammatory liver injuries,” Current Molecular Medicine, vol. 3, no. 6, pp. 545–559, 2003.
- J. Youssef and M. Z. Badr, “Role of peroxisome proliferator-activated receptors in inflammation control,” Journal of Biomedicine and Biotechnology, vol. 2004, no. 3, pp. 156–166, 2004.
- A. E. Lovett-Racke, R. Z. Hussain, S. Northrop et al., “Peroxisome proliferator-activated receptor agonists as therapy for autoimmune disease,” Journal of Immunology, vol. 172, no. 9, pp. 5790–5798, 2004.
- R. Kleemann, P. P. Gervois, L. Verschuren, B. Staels, H. M.G. Princen, and T. Kooistra, “Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFB-C/EBP- complex formation,” Blood, vol. 101, no. 2, pp. 545–551, 2003.
- J. Youssef and M. Z. Badr, “Biology of senescent liver peroxisomes: role in hepatocellular aging and disease,” Environmental Health Perspectives, vol. 107, no. 10, pp. 791–797, 1999.
- W. Klöpffer, “Environmental hazard, assessment of chemicals and products—Part II: persistence and dependability of organic chemicals,” Environmental Science and Pollution Research, vol. 1, pp. 108–116, 1994.
- T. J. Wams, “Diethylhexylphthalate as an environmental contaminant—a review,” Science of the Total Environment, vol. 66, pp. 1–16, 1987.
- W. W. Huber, B. Grasl-Kraupp, and R. Schulte-Hermann, “Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk,” Critical Reviews in Toxicology, vol. 26, no. 4, pp. 365–481, 1996.
- L. Castle, A. Mayo, and J. Gilbert, “Migration of plasticizers from printing inks into foods,” Food Additives and Contaminants, vol. 6, no. 4, pp. 437–443, 1989.
- B. C. Blount, M. J. Silva, S. P. Caudill et al., “Levels of seven urinary phthalate metabolites in a human reference population,” Environmental Health Perspectives, vol. 108, no. 10, pp. 979–982, 2000.
- J. J. Adibi, F. P. Perera, W. Jedrychowski et al., “Prenatal exposures to phthalates among women in New York and Krakow, Poland,” Environmental Health Perspectives, vol. 111, no. 14, pp. 1719–1722, 2003.
- E. K. Maloney and D. J. Waxman, “trans-activation of PPAR and PPAR by structurally diverse environmental chemicals,” Toxicology and Applied Pharmacology, vol. 161, no. 2, pp. 209–218, 1999.
- A. Molteni, B. Herndon, A. Kamal et al., “Effect of the antioxidant -tocopherol in an experimental model of pulmonary hypertension and fibrosis: administration of monocrotaline,” Nutrition Research, vol. 24, no. 9, pp. 707–720, 2004.
- S.-R. Shi, R. J. Cote, and C. R. Taylor, “Antigen retrieval immunocytochemistry: past, present, future,” Journal of Histochemistry and Cytochemistry, vol. 45, no. 3, pp. 327–343, 1997.
- J. Youssef and M. Z. Badr, “Aging and enhanced hepatocarcinogenicity by peroxisome proliferator- activated receptor alpha agonists,” Ageing Research Reviews, vol. 4, no. 1, pp. 103–118, 2005.
- F. Rahman, T. Heller, Y. Sobao et al., “Effects of antiviral therapy on the cellular immune response in acute hepatitis C,” Hepatology, vol. 40, no. 1, pp. 87–97, 2004.
- F. Magro, P. Pereira, F. Carneiro, and F. T. Veloso, “Reactive hepatitis in a patient with Crohn's disease succcessfully treated with infliximab: does tumor necrosis factor alpha play a role in reactive hepatitis?” Inflammatory Bowel Diseases, vol. 11, no. 1, pp. 88–90, 2005.
- N. K. Dhillon, Y. Sui, R. Potula et al., “Inhibition of pathogenic SHIV replication in macaques treated with antisense DNA of interleukin-4,” Blood, vol. 105, no. 8, pp. 3094–3099, 2005.
- J. Youssef and M. Z. Badr, “Extraperoxisomal targets of peroxisome proliferators: mitochondrial, microsomal, and cytosolic effects. Implications for health and disease,” Critical Reviews in Toxicology, vol. 28, no. 1, pp. 1–33, 1998.
- C.-J. Wu, L.-C. Chen, and M.-L. Kuo, “Attenuated salmonella typhimurium reduces ovalbumin-induced airway inflammation and T-helper type 2 responses in mice,” Clinical and Experimental Immunology, vol. 145, no. 1, pp. 116–122, 2006.
Copyright © 2007 Mostafa Z. Badr et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.